FDA Approved: TRELEGY ELLIPTA — Original Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved TRELEGY ELLIPTA for the treatment of chronic obstructive pulmonary disease in adults, marking approval of a fixed-dose triple inhaled therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

ORIG AP for TRELEGY ELLIPTA (FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE)